Medical Advocates
New and Noteworthy
 
June 23, 2017

Featured Report
Clinical Management Update
Drug Update
Diagnostic/Monitoring Update
Marginalized Update
US Update
Global Update
Today's Video

Home Page
Search


This web page is best viewed by using INTERNET EXPLORER
All Citations are abstracts UNLESS OTHERWISE NOTED
 
Today's Featured Report
 

The Evolving Interplay among Abundant Adipokines in Patients with Hepatitis C during Viral Clearance.
Chang ML, Hsu CM, Lin CH,et al
Nutrients. 2017 Jun 2;9(6). pii: E570.



Hepatics C Infection/Disease

 
Disease Management Update
  No one size fits all - shortening duration of therapy with direct acting antivirals for Hepatitis C genotype 1 infection.
El Sherif O, Afhdal N, Curry M.
J Viral Hepat. 2017 Jun 5.

 

Hepatics C Infection/Disease

 
Drug Update
  FULL-TEXT ARTICLE
Simeprevir with peginterferon α-2a/ribavirin for chronic hepatitis C virus genotype 1 infection in treatment-experienced patients: an open-label, rollover study.
Gane EJ, DeJesus E, Janczewska E,  et al 
BMC Infect Dis. 2017 Jun 2;17(1):

Simeprevir

 
Diagnostic/Monitoring Update
  Evaluation of the COBAS AmpliPrep/COBAS<TaqMan<sup>®</sup> HCV Test v2.0 for HCV viral load monitoring using dried blood spot specimens.
Marins EG, Bodinaidu K, Lin M, Deforest A.
J Virol Methods. 2017 May 30

 

 

 
Marginalized Update
  Hospital admissions for HIV-infected prisoners in Italy.
Pontali E, Ranieri R, Rastrelli E,et al
 nt J Prison Health. 2017 Jun 12;13(2):
 


Prisoners

 
US Update
 
Value of Comprehensive HCV Treatment among Vulnerable, High-Risk Populations.
Moreno GA, Wang A, Sánchez González Y, et al  
Value Health
. 2017 Jun;20(6):736-744.


 

Hepatics C Infection/Disease

 
Global Update
  HAART

Today's Video

Mississippi's HIV Crisis

 

 Documents identified with this icon are in Portable Document Format (PDF) and require the Adobe Acrobat Reader
 

NEW AND NOTEWORTHY
The New and Noteworthy Web features a daily interdisciplinary focus on current journal, conference,
and video reports on clinical, political, ethical, spiritual, economic, and human rights
dimensions of life-threatening infectious diseases and violence, and the related challenges to
the marginalized affected by these diseases and behaviors.